<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757376</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P41 3.1</org_study_id>
    <nct_id>NCT04757376</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis</brief_title>
  <official_title>A Double-blind, Randomized, Active-controlled, Phase 3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Double-blind, Randomized, Active-controlled, Phase 3 Study to Compare&#xD;
      Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of CT-P41 and US-licensed Prolia in&#xD;
      Postmenopausal Women with Osteoporosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, active-controlled, Phase 3 study to evaluate the&#xD;
      efficacy, PK, PD, and safety including immunogenicity of CT-P41 compared with US-licensed&#xD;
      Prolia in postmenopausal women with osteoporosis. All patients will also receive daily&#xD;
      supplementation containing at least 1,000 mg of elemental calcium and at least 400 IU vitamin&#xD;
      D from randomization to EOS visit and the data will be collected via patient's diary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 17, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>demonstrate efficacy equivalence</measure>
    <time_frame>Week 52</time_frame>
    <description>percent change from baseline in bone mineral density (BMD) for lumbar spine (L1 to L4)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>demonstrate pharmacodynamics(PD) similarity</measure>
    <time_frame>from Day 1 predose to Week 26 predose</time_frame>
    <description>area under the effect curve (AUEC) of serum carboxy-terminal cross-linking telopeptide of type I collagen (s-CTX)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Postmenopausal Women With Osteoporosis</condition>
  <arm_group>
    <arm_group_label>CT-P41</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg/mL single dose administration, Solution for injection in prefilled syringe(PFS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US-licensed Prolia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 mg/mL single dose administration, Solution for injection in PFS</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT-P41</intervention_name>
    <description>60 mg/mL single dose, Solution for injection in PFS</description>
    <arm_group_label>CT-P41</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>US-licensed Prolia</intervention_name>
    <description>60 mg/mL single dose, Solution for injection in PFS</description>
    <arm_group_label>US-licensed Prolia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women, 50 to 80 years of age, both inclusive.&#xD;
&#xD;
          2. Body weight between 40.0 and 99.9 kg, both inclusive, when rounded to the nearest&#xD;
             tenth.&#xD;
&#xD;
          3. Postmenopausal&#xD;
&#xD;
          4. Bone mineral density T-score ≤ - 2.5 and ≥ - 4.0 at the lumbar spine (L1 to L4) as&#xD;
             assessed by the central imaging vendor based on dual-energy X-ray absorptiometry(DXA)&#xD;
             scan.&#xD;
&#xD;
          5. Patients must have at least 3 vertebrae considered evaluable at the lumbar spine (L1&#xD;
             to L4) and at least 1 hip considered evaluable by DXA scan assessed by the central&#xD;
             imaging vendor. Patients with unilateral metal in hips that would be allowed for the&#xD;
             other side of 1 evaluable hip are included.&#xD;
&#xD;
          6. Patient with albumin-adjusted total serum calcium ≥ 8.5 mg/dL (≥ 2.125 mmol/L) at&#xD;
             Screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with a hypersensitivity to any component of denosumab or dry natural rubber.&#xD;
&#xD;
          2. Patient with history and/or presence of one severe or &gt; 2 moderate vertebral fractures&#xD;
             as determined by central reading of lateral spine X-ray&#xD;
&#xD;
          3. Patient with history and/or presence of hip fracture&#xD;
&#xD;
          4. Patient with history and/or presence of hyperparathyroidism or hypoparathyroidism,&#xD;
             irrespective of current controlled or uncontrolled status&#xD;
&#xD;
          5. Patient with current hyperthyroidism (unless well controlled on stable antithyroid&#xD;
             therapy)&#xD;
&#xD;
          6. Patient with current hypothyroidism (unless well controlled on stable thyroid&#xD;
             replacement therapy)&#xD;
&#xD;
          7. Patient with history and/or presence of bone disease and metabolic disease (except for&#xD;
             osteoporosis) that may interfere with the interpretation of the results&#xD;
&#xD;
          8. Patient with history and/or concurrent use of any osteoporosis treatment (other than&#xD;
             calcium and vitamin D supplements), oral or parenteral glucocorticosteroids, any bone&#xD;
             active drugs, and any investigational drug&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>KLV Arstikabinet</name>
      <address>
        <city>Parnu</city>
        <zip>80010</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

